Key result
Doubling of Lp(a) linked to ~8% higher MACE risk in angiography patients.
Why the study?
Are Lp(a) and oxidized phospholipids associated with coronary artery disease severity and cardiovascular outcomes in patients undergoing coronary angiography?
Population
1098 participants referred for coronary angiography in the CASABLANCA study
Design
Cohort
Authors
Loading...
In patients undergoing coronary angiography, higher levels of Lp(a) and oxidized phospholipids are significantly associated with multi-vessel CAD and increased risk of incident cardiovascular events.
Cohort (n=1,098)
Are Lp(a) and oxidized phospholipids associated with coronary artery disease severity and cardiovascular outcomes in patients undergoing coronary angiography?
Hazard Ratio: 1.08 (95% CI 1.03–1.14)
p-value: p=0.001
In patients undergoing coronary angiography, higher levels of Lp(a) and oxidized phospholipids are significantly associated with multi-vessel CAD and increased risk of incident cardiovascular events.
Gilliland et al. (2023) conducted a cohort in Coronary artery disease (n=1,098). Lipoprotein(a) and oxidized phospholipids vs. Lower levels (evaluated per doubling) was evaluated on Major adverse cardiovascular events (MACE; coronary revascularization, non-fatal MI, non-fatal stroke, and cardiovascular death) (HR 1.08, 95% CI 1.03-1.14, p=0.001). In patients undergoing coronary angiography, a doubling of Lp(a) was associated with an increased risk of major adverse cardiovascular events (HR 1.08; 95% CI 1.03-1.14; P=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: